Tumour infiltrating lymphocytes - Iovance Biotherapeutics/University of Texas MD Anderson Cancer Center

Drug Profile

Tumour infiltrating lymphocytes - Iovance Biotherapeutics/University of Texas MD Anderson Cancer Center

Alternative Names: Adoptive T cell therapy - Iovance Biotherapeutics/University of Texas M.D. Anderson Cancer Center; TIL - Iovance Biotherapeutics/University of Texas M.D. Anderson Cancer Center

Latest Information Update: 30 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Iovance Biotherapeutics
  • Developer Iovance Biotherapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ovarian cancer; Pancreatic cancer; Sarcoma

Most Recent Events

  • 25 Jan 2018 Iovance Biotherapeutics and the University of Texas MD Anderson Cancer Center plan a clinical trials for multiple Solid tumours
  • 13 Dec 2017 Iovance Biotherapeutics and University of Texas MD Anderson Cancer Center plans two basket studies for Sarcoma and Ovarian cancer (Platinum-resistant)
  • 24 Aug 2017 Iovance Biotherapeutics and University of Texas M.D. Anderson Cancer Center plans to initiate a phase II trial of Tumour infiltrating lymphocytes in Pancreatic cancer in December 2017 (Iovance Biotherapeutics pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top